Please assess the completion status of the following clinical trial:

Trial Title: Study for Identifying Optimal Simvastatin Formulation for Uniform Time to Maximum Plasma Concentration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* If the subject is female, she is eligible to enter and participate in this study if she is physiologically incapable of becoming pregnant or has a negative urine pregnancy test at screening and at baseline visit~* Negative Serology for Hepatitis B/C, HIV~* Non-OATP1B1\*5 carriers~* Negative Serology for anti-transglutaminase IgA antibody, and normal levels of total IgA~* For subjects with celiac disease, also~  * Diagnosis of celiac disease confirmed by medical history, histological evaluation of small intestinal mucosa on small bowel biopsy, and abnormal anti-transglutaminase antibody titers~ * Followed a gluten-free diet for at least one year, as verified by normal anti-transglutaminase antibody levels, Marsh 0-1 score on a follow-up biopsy within the past 12 months, and absence of any clinical signs or symptoms of celiac disease observed at diagnosis~Exclusion criteria:~* Current smoker or quit smoking less than 2 years ago~* Female breastfeeding or disagrees to use an effective mechanical contraceptive method (e.g. diaphragm or nonhormonal intrauterine device in combination with preservative)~* Presence of any known on-going disease which is judged to be relevant according to the investigator, besides celiac disease for the cohort of celiac patients in remission~* State after operations of the stomach or bowel (exception: appendectomy)~* Participation in any other clinical trial with investigational or approved drugs within the last month before the study~* Regular alcohol consumption of more than 25 g / day~* Use of any prescription or non-prescription drugs (including herbal supplements) must be discontinued 30 days prior to study (exceptions: paracetamol and NSAIDs, not taken longer than 2 days in a row and not taken within the last 3 days before the study)~* Consumption of grapefruit, star fruit, grapefruit juice, or star fruit juice must be discontinued 7 days prior to the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Liquid formulation of Simvastatin (Type: EXPERIMENTAL): None
- Tablet formulation of Simvastatin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).